Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.52 |
| ▸ | GLA | P06280 | 6/20 | 0.52 |
| ▸ | GAA | P10253 | 5/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | HPGD | P15428 | 6/20 | 0.49 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ERN1 | O75460 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28219087 | 0.87 | MAOB (0.47) | SRD5A1KDM4EGLAGAAMCL1 | |
| SCHEMBL3878331 | 0.84 | CA9 (0.65) | SRD5A1KDM4EGLAGAAMCL1 | |
| Hydrazine SCHEMBL28219088 | 0.82 | ESR1 (0.60) | KDM4EGLAGAAMCL1ALDH1A1 | |
| SCHEMBL11374555 | 0.81 | KDM4E (0.64) | SRD5A1KDM4EGLAGAAMCL1 | |
| SCHEMBL4342801 | 0.81 | KDM4E (0.67) | SRD5A1KDM4EGLAGAAMCL1 | |
| SCHEMBL8179535 | 0.80 | ALDH1A1 (0.67) | SRD5A1KDM4EMCL1ALDH1A1HPGD | |
| SCHEMBL4484990 | 0.76 | AURKA (0.48) | KDM4EGLAGAAMCL1ALDH1A1 | |
| SCHEMBL29074526 | 0.76 | SRD5A1 (1.00) | SRD5A1KDM4EMCL1ALDH1A1HPGD | |
| SCHEMBL11096994 | 0.76 | SRD5A1 (0.49) | SRD5A1KDM4EGLAGAAALDH1A1 | |
| SCHEMBL739294 | 0.74 | HSD17B3 (0.68) | KDM4EGLAGAAMCL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018307-B2 | Process for producing a glucuronide and genetically modified microorganisms useful in this process | UTAH STATE UNIVERSITY (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230142611-A1 | PROCESS FOR PRODUCING A GLUCURONIDE AND GENETICALLY MODIFIED MICROORGANISMS USEFUL IN THIS PROCESS | UTAH STATE UNIVERSITY (US) | 2023-05-11 | — | — | US | disclosed |
| US-20090326056-A1 | NOVEL ACTIVES AGAINST PROSTATE CARCINOMA | DSM IP ASSETS B.V. (NL) | 2009-12-31 | — | — | US | disclosed |
| EP-0840781-B1 | METHODS AND DEVICES FOR THE REMOVAL OF PSORALENS FROM BLOOD PRODUCTS | CERUS CORP (US) | 2009-12-09 | — | — | EP | disclosed |
| EP-1584622-B1 | Compounds for the photodecontamination of pathogens in blood | CERUS CORP (US) | 2009-11-11 | — | — | EP | disclosed |
| EP-1569628-B1 | NOVEL USE OF LYCOPENE FOR THE TREATMENT OF DISEASES ASSOCIATED WITH ANDROGEN SIGNALLING | DSM IP ASSETS BV (NL) | 2009-07-22 | — | — | EP | disclosed |
| EP-2020997-A2 | NOVEL ACTIVES AGAINST PROSTATE CARCINOMA | DSMIP Assets B.V. (NL) | 2009-02-11 | — | — | EP | disclosed |
| EP-1898897-A2 | METHODS AND RELATED COMPOSITIONS FOR TREATING OR PREVENTING OBESITY, INSULIN RESISTANCE DISORDERS, AND MITOCHONDRIAL-ASSOCIATED DISORDERS | Sirtris Pharmaceuticals, Inc. (US) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007131767-A2 | NOVEL ACTIVES AGAINST PROSTATE CARCINOMA | DSM IP ASSETS B.V. (NL) | 2007-11-22 | — | — | WO | disclosed |
| US-20070149466-A1 | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders | SIRTRIS PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
| WO-1996040857-A1 | METHODS AND DEVICES FOR THE REMOVAL OF PSORALENS FROM BLOOD PRODUCTS | CERUS CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5585503-A | PSORALEN COMPOUNDS | STERITECH, INC. (US) | 1996-12-17 | — | — | US | disclosed |
| US-5578736-A | SUBSTITUTED PSORALENS | STERITECH, INC. (US) | 1996-11-26 | — | — | US | disclosed |
| US-5556993-A | PSORALEN COMPOUNDS FOR DEACTIVATION OF HEPATITIS AND HIVVIRUSES | STERITECH, INC. (US) | 1996-09-17 | — | — | US | disclosed |
| WO-1996014739-A1 | COMPOUNDS FOR THE PHOTODECONTAMINATION OF PATHOGENS IN BLOOD | CERUS CORPORATION (US) | 1996-05-23 | — | — | WO | disclosed |
| EP-0707476-A1 | COMPOUNDS FOR THE PHOTODECONTAMINATION OF PATHOGENS IN BLOOD | STERITECH, INC (US) | 1996-04-24 | — | — | EP | disclosed |
| US-5399719-A | 4'-/4-Amino-2-oxa/butyl-4,5',8-trimethylpsoralen; preparation of 4'-/omega-amino-2-oxa/alkyl-4,5',8-trimethylpsoralens by reacting analogous omega-hydroxy compound with methanesulfonyl chloride and base, with sodium azide, with reducing agent | STERITECH, INC. (US) | 1995-03-21 | — | — | US | disclosed |
| WO-1995000141-A1 | COMPOUNDS FOR THE PHOTODECONTAMINATION OF PATHOGENS IN BLOOD | STERITECH, INC. (US) | 1995-01-05 | — | — | WO | disclosed |
| US-4294847-A | 8-Aminoalkyl-4-alkylisopsoralens | THOMAS C. ELDER, INC. (US) | 1981-10-13 | — | — | US | disclosed |
| US-4294822-A | 5-Aminoalkyl-4,4,8-trialkylpsoralens | THOMAS C. ELDER, INC. (US) | 1981-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142611-A1 | PROCESS FOR PRODUCING A GLUCURONIDE AND GENETICALLY MODIFIED MICROORGANISMS USEFUL IN THIS PROCESS | GUSB, UGT1A4, UGT1A6 | SRD5A1 1287/4885KDM4E 1352/4885GLA 94/4885 |
| US-12018307-B2 | Process for producing a glucuronide and genetically modified microorganisms useful in this process | GUSB, UGT1A4, UGT1A6 | SRD5A1 1287/4885KDM4E 1352/4885GLA 94/4885 |
| US-20070149466-A1 | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders | SIRT1, SIRT3, SIRT2 | SRD5A1 2602/4885KDM4E 2018/4885GLA 1759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.